Global Neurodegenerative Diseases Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Neurodegenerative Diseases market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Neurodegenerative Diseases market."
Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), leading to progressive decline in functional neurological capacities. It has a devastating effect on quality of life and independence, often requiring full-time care during the later disease stages.

The global Neurodegenerative Diseases market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Neurodegenerative Diseases volume and value at global level, regional level and company level. From a global perspective, this report represents overall Neurodegenerative Diseases market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Novartis
    Merck Serono
    Teva Pharmaceutical
    UCB
    Pfizer
    Biogen Idec
    Bayer Schering Pharma AG
    Boehringer Ingelheim
    Addex Pharmaceutical
    Amarin
    AstraZeneca
    Asubio Pharmaceutical
    Bial
    Alector
    Yumanity Therapeutics
    Eisai
    H.Lundbeck A/S
    Jiangsu Hansoh Pharmaceutical
    Yangtze River Pharmaceutical Group
    Chongqing Zein Pharmaceutical

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    NMDA
    SSRIs
    Dopamine Inhibitors

Segment by Application
    Parkinsons disease
    Huntington disease
    Amyotrophic Lateral Sclerosis
    Alzheimers disease